A Benefit-Risk Assessment of Extended-Release Oxybutynin

被引：0
作者：
Martin C. Michel
机构：
[1] University of Essen,Department of Medicine
来源：
Drug Safety | 2002年 / 25卷
关键词：
Oxybutynin; Extended Release; Tolterodine; Immediate Release; Incontinence Episode;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Oxybutynin is a muscarinic receptor antagonist, which has been available for a number of years in its original immediate-release (IR) formulation. While oxybutynin IR has proven effective for the treatment of overactive bladder, its extended use can be limited by adverse effects, particularly dry mouth.
引用
收藏
页码：867 / 876
页数：9
相关论文
共 95 条
  • [1] Goepel M(2002)Prevalence and physician awareness of symptoms of urinary bladder dysfunction Eur Urol 41 234-9
  • [2] Hoffmann J(2000)The overactive bladder Rev Contemp Pharmacother 11 1-11
  • [3] Piro M(2001)The overactive bladder BJU Int 88 135-40
  • [4] Bulmer P(2001)How widespread are the symptoms of an overactive bladder and how are they managed? a population-based prevalence study BJU Int 87 760-6
  • [5] Abrams P(2000)Socioeconomic burden of urinary incontinence with focus on overactive bladder and tolterodine treatment Rev Contemp Pharmacother 11 43-62
  • [6] Wyndaele JJ(1993)Pharmacology of lower urinary tract smooth muscles and penile erectile tissues Pharmacol Rev 45 253-308
  • [7] Milsom I(2000)Muscarinic receptor antagonists in the treatment of overactive bladder Urology 55 33-46
  • [8] Abrams P(1995)Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability Drugs Aging 6 243-62
  • [9] Cardozo L(2001)Oxybutynin and the overactive bladder World J Urol 19 319-23
  • [10] Luscombe FA(2000)The efficacy, tolerability and safety profile of tolterodine in the treatment of overactive/unstable bladder Rev Contemp Pharmacother 11 29-42
12345678910